Darolutamide monotherapy reduced prostate-specific antigen response in patients with hormone-sensitive prostate cancer while maintaining testosterone levels in a recent 24-week randomized study.
A new retrospective study examines treatment trends among men with limited life expectancy diagnosed with prostate cancer in the Veterans Affairs health system from 2000 to 2019. Researchers explored...
Researchers aimed to describe the most common symptoms of long COVID and the progression of symptoms over time. They presented their findings at IDWeek 2023 in Boston, Massachusetts.
In this COVID-19 roundup, researchers report on an increase in outpatient care following COVID-19 infection, cognition and memory impairment among those recovering from COVID-19, and more.
Researchers evaluated the association between phosphodiesterase type 5 inhibitor initiation compared with nonuse and the risk of developing AD in men with erectile dysfunction.
A team of researchers compared the presence of short-term side effects using two image-guided radiation treatment—magnetic resonance imaging-guided daily adaptive prostate stereotactic body radiotherapy...
In a post hoc analysis of two phase 3 trials, researchers set out to determine the impact of sex on tofacitinib in terms of efficacy, safety, and time to discontinuation.
